Janssen seeks expansion into psoriatic arthritis with latest Tremfya FDA filing
Tremfya is already approved across seven major markets for psoriasis and was approved for psoriatic arthritis in Japan in April...
Trending menu:
-
![Akari enrols seven out of nine patients in bullous pemphigoid trial]()
Akari enrols seven out of nine patients in bullous pemphigoid trial
-
![Cassiopea’s Winlevi uptake in acne driven by new mechanism though interest to wane]()
Cassiopea’s Winlevi uptake in acne driven by new mechanism though interest to wane
-
![AstraZeneca’s Imfinzi falls at another hurdle in non-small cell lung cancer trial]()
AstraZeneca’s Imfinzi falls at another hurdle in non-small cell lung cancer trial
-
![The most researched drugs in cystic fibrosis trials]()
The most researched drugs in cystic fibrosis trials
-
![Improved clinical efficacy found wanting in Phase III IMPALA trial]()
Improved clinical efficacy found wanting in Phase III IMPALA trial
-
![New, efficacious options offer hope for Ebola treatment and containment]()
New, efficacious options offer hope for Ebola treatment and containment
Expert commentary & analysis from GlobalData
Taltz knocks down Tremfya in head-to-head trial in psoriasis patients
ESMO 2019: Delegates told refractory metastatic renal cell carcinoma is an unmet need with great growth potential
Zensun’s Neucardin HF drug fast-tracked by FDA
Improvements to joints and skin see Taltz outscore Humira
Most Read
Company releases
3DforScience to Exhibit at the Partnering Convention, 11-13 November
BIO Europe Partnering is a premier bioscience conference, which brings nearly 5,000 delegates from a broad range of companies in...
ASTM International to Hold Board Meeting and Events in Boston on 13-16 October
Two Powerful New Stirrers by IKA
A fresh generation of hi-tech stirrers is awaiting users in the laboratory, including the RCT 5 digital, one of the...
Visuals for Bio&Health
Industry Leaders Come on Board as NMiTE Adds Engineering Expertise
The New Model in Technology and Engineering (NMiTE) has announced three appointments to its Board...
Company whitepapers
IKA Laboratory Equipment Brochure
Ika-WerkePrimary Cells Isolated from Healthy Human and Animal Tissues
Caltag MedsystemsImprove Endpoint Adjudication Efficiency with Ethical™ Adjudication®
EthicalIKA Case Study: Sustainable Processes for Textile Surfaces
Ika-WerkeSTZ-Induced Rat Model of Diabetes
Noble Life SciencesVisuals for Bio&Health
3DforScienceStudy: Comparing Efficacy and Tolerability of New Daily Oral Vitamin B12 and Intermittent Intramuscular Vitamin B12
Emisphere TechnologiesCompany A-Z
Clinical Trials
UCB’s trial of bimekizumab in psoriasis patients meets goals
UCB has announced that the Phase III BE VIVID clinical trial of its bimekizumab met all primary and key secondary endpoints in moderate-to-severe chronic plaque...
Worldwide selects ClinSpark eSource platform to automate trials
Boehringer begins enrolment in Phase II BALANCE-CF1 trial
Verona Pharma closes enrolment in Phase IIb COPD trial
Lilly’s pegilodecakin fails in Phase III pancreatic cancer trial
Drug Development
Lilly’s pegilodecakin fails in Phase III pancreatic cancer trial
Eli Lilly has reported that the Phase III SEQUOIA clinical trial of pegilodecakin failed to meet the primary endpoint of overall survival in patients with...
Novartis-Incyte’s Jakavi yields positive data in GvHD trial
Pfizer’s abrocitinib meets all endpoints in JADE MONO-1 study
ReveraGen’s vamorolone improves muscle function in DMD trial
Neurocrine reports positive long-term data for Ingrezza
Identify the key trends in the immuno-oncology market over the next two years
Go Top